← Leaderboards
Kevin Hodgetts
Yuma Therapeutics Corporation
$12,783,151
Attributed
$16,105,415
Total exposure
10
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4M · FY2014–25$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,105,415 · 10
By mechanism
U01$9,588,680 · 2
R61$1,734,272 · 2
R42$1,473,584 · 1
R21$1,300,367 · 2
R33$1,152,956 · 2
R56$855,556 · 1
Top collaborators
- Elliot J Androphy5 shared
- Christian L. Lorson5 shared
- Francisco J. Quintana3 shared
- Yukari Perrella2 shared
- Carmela R Abraham1 shared
- Marcie A Glicksman1 shared
Most similar at Yuma Therapeutics Corporation
Same institution · by research overlap
- Yukari Perrella$643,948
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposLeadBrainPropertyIn VitroIn VivoPharmaceutical PreparationsMouse ModelDoseSolubilityDesignDrug KineticsAnalogPharmaceutical ChemistryNeurodegenerative DisordersNerve DegenerationStructureBindingEvaluationProteinsS DiseaseLearningPathologyMemory
Grant awards (20)
Optimization of New Drugs for the Treatment of Essential Tremor$864,552
R61 · FY2025 · NS · contact PI
Development of Drugs that Modify CNS Innate Immunity for the Treatment of Multiple Sclerosis$434,860
R33 · FY2025 · NS
Discovery of Drugs that Modulate Neuroinflammation for the treatment of Alzheimer's Disease$859,080
U01 · FY2024 · AG · contact PI
Discovery of Drugs that Modulate Neuroinflammation for the treatment of Alzheimer's Disease$1,500,781
U01 · FY2023 · AG · contact PI
Optimization and evaluation of novel benzimidazoles for the treatment of Alzheimer's Disease$1,213,070
U01 · FY2023 · AG · contact PI
Optimization and evaluation of novel benzimidazoles for the treatment of Alzheimer's Disease$804,677
U01 · FY2023 · AG · contact PI
Development of Drugs that Modify CNS Innate Immunity for the Treatment of Multiple Sclerosis$434,860
R61 · FY2023 · NS
Discovery of Drugs that Modulate Neuroinflammation for the treatment of Alzheimer's Disease$1,609,985
U01 · FY2022 · AG · contact PI
Optimization and evaluation of novel benzimidazoles for the treatment of Alzheimer's Disease$943,599
U01 · FY2022 · AG · contact PI
Development of drugs that modify CNS innate immunity for the treatment of Multiple Sclerosis$434,860
R61 · FY2022 · NS
Discovery of Drugs that Modulate Neuroinflammation for the treatment of Alzheimer's Disease$1,770,176
U01 · FY2021 · AG · contact PI
Optimization and evaluation of novel benzimidazoles for the treatment of Alzheimer's Disease$887,312
U01 · FY2021 · AG · contact PI
Optimization of Compounds that Stabilize the SMN Protein for Treatment of SMA$212,328
R33 · FY2019 · NS
Optimization of Compounds that Stabilize the SMN Protein for Treatment of SMA$505,768
R33 · FY2018 · NS
Discovery of probes that enhance expression of the neuroprotective protein Klotho$855,556
R56 · FY2016 · AG
Optimization of Compounds that Stabilize the SMN Protein for Treatment of SMA$431,954
R21 · FY2016 · NS
Optimization of a novel series of thiazolopyridines for the treatment of SMA$420,850
R21 · FY2016 · NS · contact PI
Brain penetrant Hsp90 inhibitors for Alzheimer's disease$515,014
R42 · FY2015 · AG
Optimization of a novel series of thiazolopyridines for the treatment of SMA$447,563
R21 · FY2015 · NS · contact PI
Brain penetrant Hsp90 inhibitors for Alzheimer's disease$958,570
R42 · FY2014 · AG